News | August 05, 2021
Alembic gets USFDA nod for Clomipramine Hydrochloride
It had an estimated market size of US $ 32 million as of June 2021
It had an estimated market size of US $ 32 million as of June 2021
The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
The govt has rolled out three schemes for promoting the manufacture of API
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Turnover of API division of ISLL stood at Rs 856.58 crore
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
Subscribe To Our Newsletter & Stay Updated
